Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
77.3M
-
Number of holders
-
205
-
Total 13F shares, excl. options
-
83.1M
-
Shares change
-
+6.42M
-
Total reported value, excl. options
-
$2.6B
-
Value change
-
+$191M
-
Put/Call ratio
-
0.93
-
Number of buys
-
117
-
Number of sells
-
-95
-
Price
-
$31.30
Significant Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) as of Q2 2025
255 filings reported holding XENE - Xenon Pharmaceuticals Inc. - Common Stock as of Q2 2025.
Xenon Pharmaceuticals Inc. - Common Stock (XENE) has 205 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 83.1M shares
.
Largest 10 shareholders include FMR LLC (8.88M shares), Avoro Capital Advisors LLC (5.4M shares), BlackRock, Inc. (5.37M shares), Driehaus Capital Management LLC (4.34M shares), BRAIDWELL LP (3.61M shares), JANUS HENDERSON GROUP PLC (3.58M shares), Capital International Investors (3.18M shares), Commodore Capital LP (3.03M shares), Polar Capital Holdings Plc (2.7M shares), and WELLINGTON MANAGEMENT GROUP LLP (2.17M shares).
This table shows the top 205 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.